Gain perspectives from experts on various policy issues and therapeutic areas through our Insights series that engages multiple managed care stakeholders in video interviews.

Future of Therapy and Final Thoughts on Myelofibrosis
February 08, 2019 – 
Key leaders share their thoughts on the future of therapy as well as provide final thoughts on myelofibrosis treatment options.
 
Symptoms and Patient Progression
February 01, 2019 – 
Physicians identify the symptom progression with therapy and the patient progression with myelofibrosis.
Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
February 01, 2019 – 
Review the evolution of myelofibrosis as well as the efficacy and toxicity of the therapies.
Pacritinib and the Practical Implications
January 21, 2019 – 
Experts discuss the data available for pacritinib and the practical implications of its use.
Comparison of Ruxolitinib vs Fedratinib and Practical Implications
January 21, 2019 – 
Physicians compare the difference in mechanism between ruxolitinib and fedratinib and discuss the practical implications.
Emerging Agents and Review of Fedratinib
January 18, 2019 – 
Physicians provide an overview of the emerging agents and discuss the data available for fedratinib.
Long-Term Survival and Adverse Effects With Ruxolitinib
January 18, 2019 – 
Experts discuss the long-term survival data and adverse effect profile of ruxolitinib.
Mechanism of JAK Inhibitors and a Review of Ruxolitinib
January 11, 2019 – 
Experts identify the mechanism of JAK inhibitors and provide an overview of ruxolitinib.
NCCN Guidelines and Anemia Treatment
January 11, 2019 – 
Physicians review the National Comprehensive Cancer Network (NCCN) guidelines as well as the treatment options for anemia.
Goals of Therapy and Starting Therapy for Myelofibrosis
January 04, 2019 – 
Experts discuss the goals of therapy and provide a process for determining when to start therapy in patients with myelofibrosis.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.